Menu
Recruiting NCT05958342

CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial

Phase II Interventional Trauma Hemorrhage

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Calcium Gluconate, Vasopressin, saline placebo.
Who it may be relevant to
Registry conditions: Trauma, Hemorrhage. Basic parameters: 18 years — 90 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The CAlcium and VAsopressin following Injury Early Resuscitation (CAVALIER) Trial is a proposed 4 year, double-blind, mutli-center, prehospital and early in hospital phase randomized trial designed to determine the efficacy and safety of prehospital calcium and early in hospital vasopressin in patients at risk of hemorrhagic shock.

Detailed description

Resuscitation strategies for the acutely injured patient in hemorrhagic shock have evolved. Patients benefit from receiving less crystalloid in favor of blood transfusions with balanced ratios of plasma and platelets or whole blood resuscitation. These resuscitation practices are termed Damage Control Resuscitation and have been incorporated into resuscitation protocols in Level I trauma centers across the country. Damage Control Resuscitation represents standard practice for military and civilian trauma. Despite these changes, deaths from traumatic hemorrhage continue to occur in the first hours following trauma center arrival, underscoring the importance of early, novel interventions.

Hypocalcemia following traumatic injury is exceedingly common following severe traumatic injury in patients at risk of hemorrhagic shock. During hemorrhagic shock resuscitation, pathways reliant upon calcium such as platelet function, intrinsic and extrinsic hemostasis, and cardiac contractility are disrupted. Citrate containing transfusion products are known to further reduce calcium levels through chelation during trauma resuscitation. Hypocalcemia has consistently been shown to be independently associated with the risk of large volume blood transfusion and mortality. Current management practices include calcium replacement during the in hospital phase of care in patients receiving blood products. Early calcium replacement in patients at risk of hemorrhage and hypocalcemia may mitigate coagulopathy, maintain hemostasis, improve hemodynamics and outcomes, and may reduce complications attributable to hemorrhagic shock.

Arginine vasopressin is a physiologic hormone released by the posterior pituitary in response to hypotension and is commonly used as a vasopressor for critically ill patients for the treatment of hypotension due to multiple causes including sepsis. Prolonged hemorrhagic shock has the potential to alter systemic vasomotor tone which can progress to refractory/recalcitrant hypotension. Patients receiving resuscitation for hemorrhage are at risk of vasopressin deficiency. Vasopressin may improve hemostasis by enhancing platelet function and augmenting clot formation. Vasopressin infusion soon after injury in patients in hemorrhagic shock has been demonstrated to be safe and result in a reduction in blood transfusion requirements and a lower incidence of deep venous thrombosis.

Whole blood, red cells, and blood components are a precious and limited resource. Trauma resuscitation adjuncts such as early calcium and vasopressin may provide benefit when transfusion products are limited and may provide additional benefit even when transfusion capabilities remain robust. Due to their action on coagulation and hemodynamic cascades in the injured patient, these resuscitation adjuncts have the potential to interact and provide additive benefit to the injured patient. However, safety and efficacy of prehospital calcium and early in hospital vasopressin remain inadequately characterized. Enrolled patients may participate in the prehospital phase (calcium), in-hospital phase (vasopressin), or both. The aims of the CAlcium and VAsopressin following Injury Early Resuscitation (CAVALIER) trial are to determine the efficacy and safety of prehospital calcium supplementation and early in hospital vasopressin infusion as compared to standard care resuscitation in patients at risk of hemorrhagic shock and to appropriately characterize any additive effect of both resuscitation adjunct interventions.

Interventions

  • Drug Calcium Gluconate
    1 gram calcium gluconate provided via intravenous or intraosseous access over approximately 2-5 minutes
  • Drug Vasopressin
    4 unit vasopressin bolus followed by vasopressin infusion at 0.04 U/min for eight hours
  • Drug saline placebo
    saline placebo volume matched to prehospital or in hospital phase

Primary outcome measures

  • Number of participants with 30-day mortality [Time frame: from randomization to death or 30 days, whichever comes first]
Secondary outcome measures (12)
  • Number of participants with 6-hour mortality [Time frame: from randomization to death or 6 hours, whichever comes first]
  • Number of participants with 24-hour mortality [Time frame: from randomization to death or 24 hours, whichever comes first]
  • Number of participants with In-hospital mortality [Time frame: In hospital mortality from time of randomization to death or 30 days, whichever comes first]
  • Number of participants with Death from hemorrhage [Time frame: from randomization to death or 30 days, whichever comes first]
  • Number of participants with Death from brain injury [Time frame: from randomization to death or 30 days, whichever comes first]
  • Blood and blood component transfusion requirements in the initial 6 hours [Time frame: from randomization to 6 hours]
  • Blood and blood component transfusion requirements in the initial 24 hours [Time frame: from randomization to 24 hours]
  • Incidence of Multiple Organ Failure (MOF) [Time frame: Scores determined daily until up to Day 7 or ICU discharge, whichever comes first]
  • Incidence of nosocomial infection [Time frame: from randomization to death or 30 days]
  • Time to hemostasis [Time frame: hospital arrival to 4 hours]
  • Incidence of coagulopathy by thromboelastography (TEG) [Time frame: within 4 hours of arrival plus or minus 12]
  • Incidence of coagulopathy by thromboelastography (TEG) [Time frame: within 24 hours of arrival plus or minus 12]

Eligibility criteria

Inclusion criteria

Prehospital Phase:

Injured patients at risk of hemorrhagic shock being transported from scene or referral hospital to a participating CAVALIER trial site who meet the following criteria:

1A. Systolic blood pressure ≤ 90mmHg and tachycardia (HR ≥ 108) at scene, at outside hospital, or during anticipated transport to a participating CAVALIER trial site

OR

1B. Systolic blood pressure ≤ 70mmHg at scene, at outside hospital, or during anticipated transport to a participating CAVALIER trial site

Early In-Hospital Phase:

Injured patients at a participating CAVALIER trial site at risk of hemorrhagic shock who meet the following criteria:

1A. Systolic blood pressure ≤ 90mmHg and tachycardia (HR ≥ 108) at scene, at outside hospital, during transport, or in emergency department of a participating CAVALIER trial site

OR

1B. Systolic blood pressure ≤ 70mmHg at scene, at outside hospital, during transport, or in emergency department of a participating CAVALIER trial site

AND

2.Blood/blood component transfusion initiated in prehospital setting or deemed clinically indicated within 60 minutes of arrival at the enrolling trauma center

AND 3. Clinical team deems Operating Room for major hemorrhage control procedure (e.g., laparotomy, thoracotomy, vascular exploration or extremity amputation) indicated within 60 minutes of arrival at the enrolling trauma center

AND

4\. Anticipated admission to intensive care unit (ICU)

Exclusion criteria

Prehospital Phase

  • Wearing NO CAVALIER opt-out bracelet
  • Age > 90 or < 18 years of age
  • Isolated fall from standing injury mechanism
  • Known prisoner
  • Known pregnancy
  • Traumatic arrest with > 5 minutes of CPR without return of vital signs
  • Brain matter exposed or penetrating brain injury
  • Isolated drowning or hanging victims
  • Objection to study voiced by subject or family member at the scene or at the trauma center
  • Inability to obtain IV/IO access

Early In-Hospital Phase:

  • Wearing NO CAVALIER opt-out bracelet
  • Age > 90 or < 18 years of age
  • Isolated fall from standing injury mechanism
  • Known prisoner
  • Known pregnancy
  • Traumatic arrest with > 5 minutes of CPR without return of vital signs
  • Brain matter exposed or penetrating brain injury
  • Isolated drowning or hanging victims
  • Objection to study voiced by subject or family member at the scene or at the trauma center
  • Inability to obtain IV access

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Sequential
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

United States · 16 centers
  • Chandler Regional Medical Center — Chandler
  • University of Arizona — Tucson
  • University of Arkansas for Medical Sciences — Little Rock
  • Zuckerberg San Francisco General Hospital and Trauma Center at University of California, S — San Francisco
  • Denver Health Medical Center — Denver
  • University of Miami — Miami
  • University of Maryland, Baltimore — Baltimore
  • Hennepin County Medical Center — Minneapolis
  • … and 8 more centers

Identifiers

NCT: NCT05958342 · STUDY23040043 · W81XWH-6-D-0024

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗